Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (August 2021)

25 slides from Day One Biopharmaceuticals's investor presentation, Aug 10, 2021

  1. Slide 1: Cancer Drug Development for Patients of All Ages

    Cancer Drug Development for Patients of All Ages AUGUST 2021 Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Day One: Cancer Drug Development for Patients of All Ages

    Day One: Cancer Drug Development for Patients of All Ages A Mission that Creates Value Deep expertise in oncology, pediatric, and rare disease development, registration, and commercialization Extensive network in the global pediatric oncology community Proven track record of success in building biop

  4. Slide 4: Pediatric Markets Create Opportunity for High Impact and Capital Efficiency

    Pediatric Markets Create Opportunity for High Impact and Capital Efficiency Few approved products create potential first-in-class opportunities Pricing flexibility for important new therapies Supportive and engaged advocacy and investigator community waiting for better treatment options Early engage

  5. Slide 5: Significant Clinical and Business Momentum Over Last Months

    Significant Clinical and Business Momentum Over Last 12 Months SINGLE AGENT ACTIVITY FOR DAY 101 SENIOR LEADERSHIP APPOINTMENTS BUSINESS DEVELOPMENT/LICENSING OF MEK INHIBITORS CLINICAL PROGRAM EXPANSION RECENT ACCOMPLISHMENTS AND MILESTONES ACHIEVED Expansion of Executive Leadership Team and Board

  6. Slide 6: A Senior Team with Deep Experience in Pediatric and Adult Oncology

    A Senior Team with Deep Experience Developing and Commercializing Products in Pediatric and Adult Oncology Markets Samuel Blackman, MD, PhD Chief Medical Officer & Founder Pediatric Heme/Onc and Neuro-Onc; Oncology Clinical Development at Mavupharma, Silverback, Juno, Seattle Genetics, GSK Lisa Bowe

  7. Slide 7: Our Pipeline

    Product Candidate Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones DAY101 Type II Pan-RAF Inhibitor Pimasertib MEK1/2 Inhibitor *Includes patients ≥12 years of age FDA Breakthrough Therapy Designation FDA Orphan Drug Designation Our Pipeline INITIATED: Relapsed pLGG (FIREFLY-1)1 PLANNED: F

  8. Slide 8: DAY101: Monotherapy Approach Focused on RAF Fusions

    DAY101: Monotherapy Approach is Focused on RAF Fusions While Our Combination Strategy Addresses a Broad Set of MAPK Alterations DAY101 is a type II RAF inhibitor that selectively inhibits both monomeric and dimeric RAF kinase DAY101’s inhibition of both RAF monomers and dimers makes it a unique mono

  9. Slide 9: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor CONFIDENTIAL Source: Physician Interviews, Bandopadhayay et al. Pediatric Blood Cancer. 2014; Sievert and Fischer. J Child Neurol. 2009; ClearView Analysis. GTR: Gross Total Resection 1Molecular testing o

  10. Slide 10: PNOC014 Study Results Demonstrated Responses or Stable Disease in pLGG

    PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients Treated with DAY101 Of the eight patients with RAF fusions (7 BRAF, 1 CRAF), two patients achieved a complete response by Response Assessment for Neuro-Oncology (RANO), three had a partial response, and two a

  11. Slide 11: Results from Independent Radiology Review of PNOC014

    Results from Independent Radiology Review of PNOC014 % change from baseline RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO: Response assessment for neuro-oncology (FDA standard) Volumetric image analysis (exploratory) Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020

  12. Slide 12: Multiple Rapid, Deep and Durable Responses Observed with DAY101

    Multiple Rapid, Deep and Durable Responses Observed following Initiation of DAY101 Treatment of pLGG Patients in PNOC014 Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019

  13. Slide 13: Drug-related Adverse Events for DAY101 in PNOC014

    Drug-related Adverse Events Observed for DAY101 in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Hypophosphatemia 4 (44%) Fatigue 5 (55%) Rash 8 (89%) Achromotrichia 7 (78%) Pruritis 6 (67%) Photosensitivity 1 (11%) Nevus 7 (78%)

  14. Slide 14: Pivotal Phase 2 Study of Monotherapy DAY101 in pLGG (FIREFLY-1)

    Pivotal Phase 2 Study of Monotherapy DAY101 in pLGG (FIREFLY-1) Abbreviations: LGG, low-grade glioma; ORR, objective response rate; IRC, independent review committee; C, cycle; D, day, DLT, dose-limiting toxicity, EOS, end of study, MRI, magnetic resonance imaging; SOA, schedule of assessments; SOC,

  15. Slide 15: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    Incidence and Prevalence of BRAF-altered pLGG in the U.S. US Census CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis SEER US complete prevalence counts of patients aged under 25 with Brain and Other Nervous Systems tumors as of January 1, 2017 Selumetinib pLGG trial (Fangusaro et

  16. Slide 16: Our Pipeline

    Product Candidate Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones DAY101 Type II Pan-RAF Inhibitor Pimasertib MEK1/2 Inhibitor *Includes patients ≥12 years of age FDA Breakthrough Therapy Designation FDA Orphan Drug Designation Our Pipeline INITIATED: Relapsed pLGG (FIREFLY-1)1 PLANNED: F

  17. Slide 17: DAY101 Clinical Activity in Adult Cancers

    Clinical activity demonstrated in relapsed melanoma patients; preclinical activity demonstrated in RAF fusions, BRAF non-V600 mutations, and BRAF V600 mutations Source: Olszanski AJ et. al. European Society for Medical Oncology Congress; Poster #410P, 2017 Unpublished clinical study results Less fre

  18. Slide 18: Next-generation RAF Inhibitors Address Adult Cancers with RAF Wild-type Fusions

    Botton T et al, Cell Reports, 2019 LY3009120: Lilly pan-RAFi Lifirafenib: Beigene pan-RAF/EGFRi CCT196969: CRUK RAF ”paradox breaker” Springworks 2020 Corp Presentation BRAFwt fusion mixed Mullerian cancer BRAFwt fusion, melanoma Day One/CrownBio internal data E5251-U2001 (Sep 2020) Only DAY101 has

  19. Slide 19: Scientific Rationale for Combining DAY101 with MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining DAY101 with Additional MAPK Pathway Inhibitors Potential combinations Type II RAFi + MEKi Rationale BRAF fusion dimers are effectively inhibited by type II, but not type I RAFi MEK ERK RAF/MEK/ ERK PI3K/mTOR RAL Type II RAFi + Targeting multiple nodes of MAP

  20. Slide 20: Pimasertib: Allosteric MEK1/2 Inhibitor

    Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors Sources: Pimasertib Investigator Brochure, v12, 2019; de Gooijer et al., Int J Cancer, 2018; Shaw et al., AACR LB-456, 2012; Lebbe et al., Cancers, 2020. Source: Hepner, Salgues, Anjos, et al. 2017. GF RTK

  21. Slide 21: Vertical MAPK Pathway Inhibition with DAY101 and Pimasertib

    Vertical MAPK Pathway Inhibition with DAY101 and Pimasertib Unlocks Potential Synergy for Adult Solid Tumors The MAPK pathway normally has multiple feedback loops that negatively regulate upstream (RAS/RAF) activation to ensure optimal signaling. Monotherapy MEK inhibition disables these feedback lo

  22. Slide 22: DAY101 + Pimasertib Combo Dose Escalation

    DAY101+ Pimasertib Combo Dose Escalation Pimasertib Combined with DAY101 May Have a Rapid Path to Market Biomarker-positive patients Substudy 1: DAY101 Substudy 2: DAY101+ Pimasertib Screening Enrollment Treat until progression, toxicity or withdrawal of consent Safety Follow-up BRAFwt fusion melano

  23. Slide 23: Financial Summary: DAWN

    $ Millions Three Months Ended 6/30/21 Three Months Ended 6/30/20 R&D Expense $9.9 $1.4 G&A Expense $5.5 $0.9 Net Loss $15.4 $2.3 Cash and cash equivalents as of June 30, 2021: $310.0 million (no debt) IPO on May 26, 2021: $184 million in gross proceeds, includes full exercise of underwriter’s option

  24. Slide 24: Re-envisioning and Redefining Drug Development for People of All Ages

    Re-envisioning and Redefining Drug Development for People of All Ages – Starting at Day One DAY101 Oral, CNS-penetrant, pan-RAF PIMASERTIB Oral, allosteric MEK inhibitor SPECIALIZED TEAM pLGG: most common brain tumor in children, with no approved therapies Rapid and durable responses demonstrated in

  25. Slide 25: Slide 25

Day One Biopharmaceuticals — Investor Presentation (August 2021) on 6ix